Intracellular Ownership
| ITCI Stock | USD 85.45 0.19 0.22% |
Shares in Circulation | First Issued 2012-09-30 | Previous Quarter 103.7 M | Current Value 105.8 M | Avarage Shares Outstanding 58.9 M | Quarterly Volatility 27 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Intracellular |
Intracellular Stock Ownership Analysis
About 96.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.87. Intracellular Th had not issued any dividends in recent years. Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people. To learn more about Intracellular Th call Sharon Mates at 646 440 9333 or check out https://www.intracellulartherapies.com.Besides selling stocks to institutional investors, Intracellular also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Intracellular's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Intracellular's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Intracellular Quarterly Liabilities And Stockholders Equity |
|
Intracellular Insider Trades History
Roughly 2.0% of Intracellular Th are currently held by insiders. Unlike Intracellular's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Intracellular's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Intracellular's insider trades
Intracellular Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Intracellular is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intracellular Th backward and forwards among themselves. Intracellular's institutional investor refers to the entity that pools money to purchase Intracellular's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Clearbridge Advisors, Llc | 2024-06-30 | 1.7 M | Geode Capital Management, Llc | 2024-06-30 | 1.7 M | Perceptive Advisors Llc | 2024-09-30 | 1.6 M | Deep Track Capital, Lp | 2024-09-30 | 1.6 M | Franklin Resources Inc | 2024-06-30 | 1.6 M | Suvretta Capital Management, Llc | 2024-06-30 | 1.6 M | Holocene Advisors, Lp | 2024-06-30 | 1.5 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.4 M | Alyeska Investment Group, L.p. | 2024-06-30 | 1.4 M | Fmr Inc | 2024-09-30 | 11.1 M | Vanguard Group Inc | 2024-09-30 | 9.6 M |
Intracellular Th Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intracellular insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intracellular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intracellular insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Intracellular's latest congressional trading
Congressional trading in companies like Intracellular Th, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Intracellular by those in governmental positions are based on the same information available to the general public.
| 2024-07-09 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Intracellular Outstanding Bonds
Intracellular issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Intracellular Th uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Intracellular bonds can be classified according to their maturity, which is the date when Intracellular Th has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Intesa Sanpaolo 571 Corp BondUS46115HAW79 | View | |
| ISPIM 77 Corp BondUS46115HAU14 | View | |
| ISPIM 3875 12 JAN 28 Corp BondUS46115HBD89 | View | |
| ISPIM 4375 12 JAN 48 Corp BondUS46115HBE62 | View |
Intracellular Corporate Filings
F4 | 14th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 10th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.87) | Revenue Per Share 6.096 | Quarterly Revenue Growth 0.39 | Return On Assets (0.07) | Return On Equity (0.1) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.